Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study

Nubeqa (darolutamide) - Bayer, Orion Corp

docetaxel (CPC634) - Cristal Therap

https://www.urologenportal.de/fileadmin/MDB/PDF/Presse/2023/neuHP_DGU2023_230903.pdf

Hammerer, P; Rezazadeh Kalebasty, A; Tombal, B; Hussain, M; Saad, F; Fizazi, K; Sternberg, C.N; Crawford, E.D; Kapur, S; Zhang, W; Ploeger, B; Li, R; Kuss, I; Zieschang, C; Wittemer-Rump, S; Smith, M.R

Sep 8, 2023